OverviewSuggest Edit

ChemoCentryx is a biopharmaceutical company focused on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases, and cancer. It focuses on orphan and rare diseases, chronic kidney disease, immuno-oncology, and other inflammatory diseases.
TypePublic
Founded1997
HQSan Carlos, CA, US
Websitechemocentryx.com
Employee Ratings2.7

Latest Updates

Employees (est.) (Dec 2020)133(+63%)
Job Openings48
Revenue (FY, 2020)$64.9 M(+80%)
Share Price (May 2022)$19.2(+11%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at ChemoCentryx

Thomas J. Schall

Thomas J. Schall

President, Chief Executive Officer and Chairman of the Board
Susan M. Kanaya

Susan M. Kanaya

Executive Vice President, Chief Financial and Administrative Officer and Secretary
Markus J. Cappel

Markus J. Cappel

Chief Business Officer and Treasurer
Dalia R. Rayes

Dalia R. Rayes

Senior Vice President, Head of Commercial
Rita I. Jain

Rita I. Jain

Executive Vice President, Chief Medical Officer and Director
Sangita Ghosh

Sangita Ghosh

Senior Vice President, Technical Operations
Show more

ChemoCentryx Office Locations

ChemoCentryx has an office in San Carlos
San Carlos, CA, US (HQ)
835 Industrial Rd #600
Show all (1)

ChemoCentryx Financials and Metrics

ChemoCentryx Revenue

ChemoCentryx's revenue was reported to be $64.89 m in FY, 2020 which is a 79.6% increase from the previous period.
USD

Revenue (Q3, 2021)

17.7m

Net income (Q3, 2021)

(22.3m)

EBIT (Q3, 2021)

(21.8m)

Market capitalization (13-May-2022)

1.3b

Closing stock price (13-May-2022)

19.2

Cash (30-Sept-2021)

93.7m

EV

1.3b
ChemoCentryx's current market capitalization is $1.3 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

42.9m36.1m64.9m

Revenue growth, %

(48%)(16%)80%

General and administrative expense

20.4m24.2m42.2m

R&D expense

62.7m70.3m77.9m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

8.3m7.2m10.6m6.0m49.4m5.1m10.4m1.8m17.7m

General and administrative expense

5.5m5.6m6.1m8.8m10.3m10.4m16.3m19.7m19.6m

R&D expense

15.4m17.6m18.1m19.3m18.8m18.6m23.4m20.9m19.9m

Operating expense total

20.9m23.2m24.2m28.1m29.1m28.9m39.7m40.6m39.5m
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

28.1m39.2m32.3m

Accounts Receivable

176.0k137.0k

Current Assets

181.4m174.4m441.6m

PP&E

1.5m2.2m25.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

79.3m38.7m35.9m59.4m333.2m56.2m68.5m77.2m93.7m

Accounts Receivable

153.0k156.0k44.0k130.0k118.0k52.0k

Current Assets

226.7m202.0m172.5m186.7m507.2m474.4m390.6m317.1m293.4m

PP&E

1.4m1.5m1.6m2.7m5.6m15.1m33.1m33.8m33.0m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(38.0m)(55.5m)(55.4m)

Depreciation and Amortization

512.0k550.0k797.0k

Accounts Payable

(434.0k)188.0k3.0m

Cash From Operating Activities

16.4m(70.1m)(81.1m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

(11.9m)(27.1m)(40.0m)(21.7m)(1.4m)(25.5m)(29.7m)(68.9m)(91.2m)

Depreciation and Amortization

141.0k276.0k413.0k143.0k275.0k402.0k117.0k1.1m2.1m

Accounts Payable

327.0k8.0k(29.0k)1.0m370.0k213.0k1.2m2.6m68.0k

Cash From Operating Activities

(18.3m)(33.2m)(49.9m)(27.4m)(45.8m)(61.9m)(21.6m)(39.4m)(64.7m)
USDFY, 2018

Revenue/Employee

564.1k

Debt/Equity

1.3 x

Debt/Assets

0.1 x

Financial Leverage

12.4 x
Show all financial metrics

ChemoCentryx Operating Metrics

FY, 2018FY, 2019FY, 2020

Office and Laboratory Space, square feet

35.76 k132.22 k132.22 k

Patent Applications

362420525

Patents (Other)

495431

Patents Issued

849905953
Show all operating metrics

ChemoCentryx Acquisitions / Subsidiaries

Company NameDateDeal Size
ChemoCentryx Ireland Limited
ChemoCentryx Limited

ChemoCentryx Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

ChemoCentryx Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

ChemoCentryx Online and Social Media Presence

Embed Graph

ChemoCentryx News and Updates

ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis

SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS® (avacopan), an orally admi…

Thinking about buying stock in Draftkings, ChemoCentryx, Opendoor Technologies, 1life Healthcare, or Enservco Corp?

NEW YORK, May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DKNG, CCXI, OPEN, ONEM, and ENSV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022

-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic (PD) results show CCX559 exhibits immune stimulatory properties in cancer patients --

(CCXI Alert) Should Management be Held Accountable for ChemoCentryx Investors Losses? Contact Johnson Fistel

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx, Inc. ("ChemoCentryx" or "the Company") (NASDAQ: CCXI) against certain of its officers and directors.

ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conferenc…

CHEMOCENTRYX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ChemoCentryx, Inc. - CCXI

NEW ORLEANS, Feb. 18, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into ChemoCentryx, Inc. (NasdaqGS: CCXI). On May 4, 2021, the U.S....
Show more

ChemoCentryx Blogs

ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference

ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference Content Import Mon, 05/16/2022 - 08:30 ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference 05/16/22 General SAN CARLOS, Calif., May 16, 2022 (GLOBE…

ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights

-- Five-fold increase in net sales of TAVNEOS ® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique Prescribers - 308% Patients on Drug -- -- Global

ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022

ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022 Content Import Thu, 04/28/2022 - 08:30 ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022 04/28/22 General …

ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS ® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis -- -- TAVNEOS also approved in European Union (EU) triggering

ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights

-- U.S. Food & Drug Administration (FDA) approves TAVNEOS TM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- -- TAVNEOS approved also in Japan ; European CHMP opinion expected this month -- -- Pipeline advances: Company intends to meet with FDA on pa…

ChemoCentryx Reports Second Quarter 2021 Financial Results and Recent Highlights

-- Company filed an amendment to its NDA for avacopan in the treatment of ANCA-associated vasculitis; PDUFA goal date extended to October 7, 2021 -- -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis also under review by the European Medicines Agency and the Japan
Show more

ChemoCentryx Frequently Asked Questions

  • When was ChemoCentryx founded?

    ChemoCentryx was founded in 1997.

  • Who are ChemoCentryx key executives?

    ChemoCentryx's key executives are Thomas J. Schall, Susan M. Kanaya and Markus J. Cappel.

  • How many employees does ChemoCentryx have?

    ChemoCentryx has 133 employees.

  • What is ChemoCentryx revenue?

    Latest ChemoCentryx annual revenue is $64.9 m.

  • What is ChemoCentryx revenue per employee?

    Latest ChemoCentryx revenue per employee is $487.9 k.

  • Who are ChemoCentryx competitors?

    Competitors of ChemoCentryx include Precision Medicines, NOXXON Pharma and Telix Pharmaceuticals.

  • Where is ChemoCentryx headquarters?

    ChemoCentryx headquarters is located at 835 Industrial Rd #600, San Carlos.

  • Where are ChemoCentryx offices?

    ChemoCentryx has an office in San Carlos.

  • How many offices does ChemoCentryx have?

    ChemoCentryx has 1 office.